Bodal Chemicals Limited (BODALCHEM)
Investor Presentation
AI summary
- H1FY27 consolidated revenue Rs 15,991 mn +67% y-y; Q2FY27 Rs 8,840 mn +77% y-y
- H1FY27 EBITDA Rs 2,027 mn +114% y-y; Q2FY27 EBITDA Rs 1,276 mn +197% y-y; margins improved to 12.7% H1, 14.4% Q2
- H1FY27 PAT Rs 1,118 mn +620% y-y; Q2FY27 PAT Rs 814 mn +1259% y-y
- Dye intermediates revenue grew 68% H1FY27; Basic chemicals up 136% y-y; Chlor alkali up 6% y-y
- Subsidiaries BCTPL and Bodal China showed strong growth; Sener Boya stable
- Management expects continued strong performance due to China structural changes and benzene downstream plant stabilization
- Net debt/equity improved to 0.67x in FY26; ROE 4.1% FY26
- Capacity ~470,000 MTPA with ongoing expansions and integrated manufacturing
- Company focuses on backward integration, cost competitiveness, and international market expansion
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 BODALCHEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add BODALCHEM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Bodal Chemicals Limited
Important.
The summary above is generated automatically from Bodal Chemicals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.